Browse by author
Lookup NU author(s): Professor Tiago OuteiroORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
© 2018 - IOS Press and the Authors. All Rights Reserved. Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-Time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.
Author(s): Konig A, Miranda HV, Outeiro TF
Publication type: Review
Publication status: Published
Journal: Journal of Parkinson's Disease
Year: 2018
Volume: 8
Issue: 1
Pages: 33-43
Online publication date: 17/02/2018
Acceptance date: 17/01/2018
ISSN (print): 1877-7171
ISSN (electronic): 1877-718X
Publisher: IOS Press
URL: https://doi.org/10.3233/JPD-171285
DOI: 10.3233/JPD-171285
